Pharmaceutical Company is looking for a strategic partner (Company Valuation – INR 100-120 crore)

Company Background



Brief background

Company is engaged in manufacturing of dry powder injection, dry powder syrup and sterile water for injection. Further, upgradation of unit is under process for manufacturing of large volume parentals.



Business model

Company is working under CDMO model (For Dry Powder Injection and Dry Powder Syrup) and is engaged in manufacturing goods for various pharma giants such as Aristo, Akums, Glenmark, Mankind etc. CDMO Business works under a cost plus model and Company bears a minimal risk of changes in API pricing

For Sterile water for injection, company is selling products on P2P basis




Product and Plant

One Unit is established for manufacturing various ranges of Beta Lactam for Dry Injection and Dry Syrup and another unit is engaged in manufacturing of Sterile water for injection and Large Volume parentals. Company facility is a WHO-GMP approved and Schedule M Compliant.

Further, Audit of various African countries is under process

Financial data



Figures INR crores



Strategic Partner

Why?

The company has ventured into a new product portfolio with significant potential. Therefore, we need professional people to run the company effectively.

Partner Type

We are seeking a strategic partner who is willing to invest in our ongoing business. The ideal partner should be committed to working collaboratively to drive the development and growth of our company.

Investment Modalities

Transfer of existing stake of promoters or fresh issuance through private placement. Percentage of stake to be transferred can be discussed mutually.

Value Proposition for Strategic Investors

The company is a listed entity, providing strategic investors with liquidity in their investment and the potential for net worth appreciation

Indian CDMO Market



Source: Akums Investor presentation for Q4 earnings

Indian CDMO Market: Multiple Drivers to Accelerate Growth

"Health consumerism" driven by increasing affordability

Augmented demand for specialized offerings that can be fulfilled by CDMO partners providing "customized" solutions

Supplier consolidation among branded generic players

Increased need for large "preferred" CDMO partners to minimize sourcing hassles

Heightened regulatory stringency

Reliable "quality-focused" CDMO players needed to ensure compliance to dynamic and stringent regulations

Increased outsourcing - R&D and manufacturing activities

Large branded generic pharmaceutical companies are focusing on sales and marketing to drive growth

Capital intensive infrastructural requirements

Entry barriers for players who lack scale or do not view manufacturing as a core business play

Patent cliff and increasing specialization

Timely approvals and ability to offer complex offerings are key differentiators for CDMO players

Emergence of organized pharmacy chains and D2C consumer health brands

Players sourcing from quality CDMO players to offer differentiated alternatives to their customers



Source: Akums Investor presentation for Q4 earnings

Thank you